Pin Xiang, PharmD

Boehringer Ingelheim

Poster(s):

• (268) Economic impact of experiential negative symptoms among patients living with schizophrenia: Medical expenditure panel survey
  Wednesday, October 29, 2025

• (269) Healthcare resource utilization and costs of schizophrenia among Medicaid beneficiaries
  Wednesday, October 29, 2025